MYX 2449
Alternative Names: MYX-2449; Trastuzumab-N-Myristoyltransferase inhibitor ADC; Trastuzumab-NMT inhibitor ADC; Trastuzumab-NMTi ADCLatest Information Update: 19 Apr 2023
At a glance
- Originator Myricx Pharma
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Glycylpeptide N-tetradecanoyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 19 Apr 2023 Preclinical trials in Cancer in United Kingdom (IV)
- 18 Apr 2023 Pharmacodynamics data from a proof of concept preclinical trial in Cancer released by Myricx Pharma
- 17 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at American association for cancer research (AACR-2023)